Caribou Biosciences (CRBU) Institutional Ownership

During the previous two years, 109 institutional investors and hedge funds held shares of Caribou Biosciences. The most heavily invested institutionals were Avidity Partners Management LP ($36.44M), Vanguard Group Inc. ($21.13M), Deerfield Management Company L.P. Series C ($16.73M), PFM Health Sciences LP ($8.44M), Alkeon Capital Management LLC ($7.86M), Kynam Capital Management LP ($5.11M), and Silverarc Capital Management LLC ($4.27M).Learn more on CRBU's institutional investors.

77.51% of Caribou Biosciences stock is owned by institutional investors. Learn more on CRBU's institutional investor holdings.

Of the 94 institutional investors that purchased Caribou Biosciences stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Avidity Partners Management LP ($3.60M), Deerfield Management Company L.P. Series C ($3.50M), JPMorgan Chase & Co. ($2.06M), Assenagon Asset Management S.A. ($1.89M), Renaissance Technologies LLC ($1.48M), Jacobs Levy Equity Management Inc. ($1.44M), and Vanguard Group Inc. ($1.41M).

Institutional investors have bought a total of 28,291,140 shares in the last 24 months. This purchase volume represents approximately $96.40M in transactions.

Of the 38 institutional investors that sold Caribou Biosciences stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Bank of America Corp DE ($2.80M), Assenagon Asset Management S.A. ($2.70M), Point72 Asset Management L.P. ($2.45M), Elmwood Wealth Management Inc. ($1.87M), Candriam S.C.A. ($520K), Jane Street Group LLC ($374.81K), and Dimensional Fund Advisors LP ($321.87K).

Institutional investors have sold a total of 13,067,528 shares in the last 24 months. This volume of shares sold represents approximately $33.30M in transactions.